Molecular Partners’ Chief Executive Officer
Cowen Health Care Conference Presentation Details:
Novel Oncology Targets Corporate Panel Discussion:
Time:
Fireside Chat Q&A:
Time:
Webcasts of the Panel discussion as well as the fireside chat can be accessed through the investors section of the
Leerink Global Biopharma Conference Participation Details:
Date:
Location:
Full Year 2023 Results Release Date and Time:
Full Year 2023 Conference Call Details:
The full year 2023 results presentation will also be webcast live and will be made available on the Company’s website under the investors section. The replay will be available for 90 days following the presentation.
In order to register for the full year 2023 conference call on
PARTICIPANT DIAL IN (TOLL FREE): | 1-866-652-5200 |
PARTICIPANT INTERNATIONAL DIAL IN: | 1-412-317-6060 |
Switzerland Toll Free: | 0800-246787 |
About
For further details, please contact:
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Zurich-Schlieren,
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners’ product candidates, the selection and development of future programs, and Molecular Partners’ expected business and financial outlook, including expenses and cash utilization for 2023 and its expectation of its current cash runway. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, “would” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners’ reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners’ ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners’ preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ intellectual property position; Molecular Partners’ ability to identify and in-license additional product candidates; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners’ Annual Report on Form 20-F for the fiscal year ended
Source:
2024 GlobeNewswire, Inc., source